Researchers at KTH Royal Institute of Technology are planning the clinical trial of a new treatment for nonalcoholic fatty liver disease and type 2 diabetes which harnesses liver cells’ own ability to burn accumulated fats.
In a study involving 86 people with varying degrees of fatty liver disease, researchers from KTH(SciLifeLab) research center and Gothenburg University found that the liver has the ability to burn up accumulated fats. The researchers propose a mixture of substances that will set this process in motion.
KTH Assistant Professor, a SciLifeLab fellow, says the team’s metabolic modeling approach, which relied on data from Swedish-based project, can be used for a number of chronic liver diseases. Human Protein Atlas project director and KTH Professor Mathias Uhlén also co-authored the paper.
“Our approach combined systems biology and clinical medicine in a manner not previously done,” Mardinoglu says.
One of the most common chronic liver problems in the world, the accumulation of fat in the liver – or hepatic steatosis – is the key characteristic of non-alcoholic fatty liver disease (NAFLD). It is linked to obesity, insulin resistance, type 2 diabetes and cardiovascular diseases. Up to 30 percent of subjects with NAFLD develop non-alcoholic steatohepatitis (NASH) in which hepatic inflammation and scarring can lead to cirrhosis and liver cancer.
The researchers mapped the metabolic changes caused by accumulated fat in 86 patients’ liver cells, and combined this data with an analysis of a genome-scale model of liver tissue. Doing so enabled them to identify the precise metabolic changes individual patients’ liver cells undergo due to fat.
Mardinoglu is one of the researchers who had earlier established a oxidation of fat and synthesis of the antioxidants.. A proof of concept test showed that accumulated liver was burned off by treating human subjects with a “cocktail” that increases
Based on the results from the study, an improved intervention using a portfolio of substances has been designed. “This mixture can potentially decrease the amount of the fat accumulated in the liver,” Mardinoglu says. “There is no such drug available at present and we are planning for further clinical trials later this year.”
The researchers believe that the mixture of substances could also be used to treat accumulated liver fat due to alcoholic fatty liver disease and type 2 diabetes. “Considering NAFLD and diabetes are common conditions that regularly co-exist and can act synergistically to drive adverse outcomes, such a mixture of substances might also be used in the treatment of subjects with diabetes,” says co-author, Ulf Smith of University of Gothenburg.
Uhlén adds: “I am extremely pleased that the resource created through the Human Protein Atlas effort has been used in the analysis of clinical data obtained from NAFLD patients, and that this analysis has led to the design of a mixture of substances that can be used for treatment of this clinically important patient group.”